PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: PathXL

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

‘Dolly the Sheep’ Business Mastermind Joins PathXL - PathXL welcomes one of UK’s leading medtech minds onto their Board - PathXL.com
‘Dolly the Sheep’ Business Mastermind Joins PathXL

 

NewswireToday - /newswire/ - Belfast, Northern Ireland, Ireland, 2013/01/22 - PathXL welcomes one of UK’s leading medtech minds onto their Board - PathXL.com. NYSE: PHG, AEX: PHIA

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

One of the leading names in the UK’s healthcare technology sector, Professor Simon Best, has joined the Board of PathXL. The Northern Ireland Science-Park based company, a Queen’s University Belfast spin-out, is a pioneer in the use of web-based solutions for digital pathology.

Chief Executive Des Speed said:
“We are really delighted to welcome someone of Simon’s stature, with over 27 years’ experience in the healthcare, food and agriculture, chemicals and industrial biotechnology sectors, to the PathXL board.

“In this time, he has founded several major bio-pharmaceutical and med-tech businesses and gained significant entrepreneurial and senior management experience in raising finance, deal formation and product commercialisation.

“Simon’s expertise will clearly help PathXL grow as a company and progress the delivery of new patented technology and new products that we plan to take to market in a very assertive way.”

As CEO, it was Prof Best, who was responsible at Roslin Biomed for the commercialisation of the technology used to create Dolly the sheep. Overall, he has helped raise over £170m for lifescience companies in the past 15 years through Angel and Venture fund-raisings, trade-sales and flotations on both AIM and the main-board London Stock Exchange.

Prof Best said:
“I am delighted to be joining the Board of such an exciting young company. PathXL is at the leading-edge of digital pathology which is a ‘hot’ field whose time has definitely come.

“The company is poised to speed up the diagnosis and selection of targeted therapies for patients thereby generating very substantial financial returns to its investors.”

PathXL (pathxl.com), who recently announced a new seven-figure investment into the further development of its innovative digital pathology software, have new projects coming up in 2013 on image analysis.

One of the investors is Crescent Capital and Bob McGowan-Smyth has also just joined the PathXL board to represent the NI-based investment company.

Mr McGowan-Smyth is an experienced venture capitalist and has been a Board member of over 20 commercial organisations. His specialties are: private equity, venture capital, non-executive director, strategic and business planning, mergers and acquisitions, HR issues, management and financial accounting and branding.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: PathXL

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


‘Dolly the Sheep’ Business Mastermind Joins PathXL

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

PathXL |
Publisher Contact: Press Office - PathXL.com 
+44(0)28 9073 8712 sales[.]pathxl.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any PathXL securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From PathXL / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)